335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 28690 | Nieves Martinez Chanza | prostate | AstraZeneca | CAPItello-281 | Trial closed for recruitment | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | ||
| 29417 | Smoldering myeloma defined by IMWG 2014 criteria Diagnosed less than 1 year before the inclusion |
Nathalie Meuleman | Myeloma | IFM | CARRISMM | Trial closed for recruitment | Evaluation of the impact of the update multiple myeloma criteria on the natural history of smoldering myeloma in order to establish new recommendations about follow-up and prognostic evaluation of smoldering myeloma | nathalie.meuleman@hubruxelles.be | |||
| 29766 | Nuria Kotecki | Multiple | Unicancer | CHANCES-IPC 2021-008 | Trial open for recruitment | A phase 1 first-in-human study of the anticd73 iph5301 alone or in combination with chemotherapy and trastuzumab in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | ||
| 22831 | Not eligible for surgery | Alain Hendlisz | Liver | BMS - Bristol Myers Squibb int. | CheckMate | Trial closed | A Randomized, Multi-center Phase III Study of Nivolumab versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 459) | alain.hendlisz@hubruxelles.be | 3 | 3 | |
| 22745 | metastatic, RECIST 1.1 | Alain Hendlisz | Colon | BMS - Bristol Myers Squibb int. | Checkmate 142 | Trial closed for recruitment | CA209-142 A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations, in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and non-MSI-H Colon Cancer. Checkmate 142 | alain.hendlisz@hubruxelles.be | 2 | 2 | |
| 22740 | MSI high/Mismatch Repair Deficient | Alain Hendlisz | Colon | BMS - Bristol Myers Squibb int. | CheckMate 8HW: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 8HW | Trial closed for recruitment | A Phase 3b Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or an Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer. | alain.hendlisz@hubruxelles.be | 3 | 3 | |
| 22695 | Treatment by checkpoint inhibitor will be necessary | Dirk Van Gestel | Solid tumors | UZ-Gent | CHEERS -EC2017/1678 | Trial closed | CHEckpoint inhibition in combination with an immunoboost of External body Radiotherapy in Solid tumors: CHEERS-trial | accueil.cons.radiotherapie@hubruxelles.be | 2 | 2 | |
| 22614 | Status WHO < 2. Adjuvant | Gabriel Liberale | Ovary | Unicancer | CHIPOR | Trial closed for recruitment | CHIPOR : randomized phase III study evaluating hypertermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse | gabriel.liberale@hubruxelles.be | 3 | 3 | |
| 22629 | all tumor types, any treatment line. | Alain Hendlisz | Multiple | Bordet | CHRONOS & KAIROS | Trial open for recruitment | CHRONOS & KAIROS Project : Creation of a Prospective Combined Clinical and Biological Database to Capture in Parallel the Patient?s Clinical History AND Tumoral Qualitative and Quantitative Changes During the Course of the Disease | alain.hendlisz@hubruxelles.be | 3 | 3 | |
| 22643 | 2nd to 4th line / at least 1 bi-dimensionaly measurable lesion/ HbA1c <= 8,5% at screening | Marie Maerevoet | Non-Hodgkin lymphoma | Bayer | CHRONOS-4 | Trial closed for recruitment | A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL) | marie.maerevoet@hubruxelles.be | 3 | 3 | |
| 29761 | Breast | UCL St Luc | CICLIBIOME | Trial open for recruitment | CICLIBIOME : A study of the association of the microbiome with treatment outcome of CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer | ||||||
| 22631 | Treatment with SIR-sphères microspheres | Patrick Flamen | Liver | CIRSE | CIRT | Trial closed | CIRSE Registry for SIR-Spheres Therapy (CIRT) | patrick.flamen@hubruxelles.be | |||
| 29646 | Thierry Berghmans | Lung | Inhatarget Therapeutics | CIS-DPI-01 | Trial open for recruitment | A Phase I/IIa First-in-Human Single-arm Open-label Multicentre Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of a Cisplatin-based Formulation Administered as Dry Powder for Inhalation in Combination with First Line Standard of Care in Patients with Stage IV Non-Small Cell Lung Cancer (CIS-DPI-01) | 1/2a | 1 | |||
| 22673 | MCL - at least 1 but no more than 3 prior systemic treatment regimens | Marie Maerevoet | Non-Hodgkin lymphoma | Incyte Corporate | CITADEL-205 | Trial closed | A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kdelta Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) | marie.maerevoet@hubruxelles.be | 2 | 2 |